Key facts
- This page summarizes Kimi Iguchi's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Feb 2024, 17:02.
Kimi Iguchi - 13 Feb 2024 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)
- Reporting relationship
- CFO & Treasurer
- Issuer ticker
- SAGE
- Reported as of
- 13 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Feb 2024, 17:02:05 UTC
- Prior SEC filing
- 04 Jan 2024
- Next SEC filing
- 07 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Kimi Iguchi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kimi Iguchi filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 15 Feb 2024.
Change
- Previous filing in this sequence was filed on 04 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SAGE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +11,250
- Change %
- +16%
- Price
- $0.000000
- Shares after
- 81,679
- Date
- 13 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SAGE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +22,500
- Change %
- Price
- $0.000000
- Shares after
- 22,500
- Date
- 13 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,500
- Exercise price
- $23.02
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Consists of shares of common stock issuable under 11,250 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on February 13, 2025.
Footnote F2
The securities awarded on February 13, 2024 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,625 shares of common stock shall vest on the one year anniversary of February 13, 2024, with 16,875 shares vesting in 36 equal monthly installments thereafter.